These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. MANAGEMENT OF ENDOCRINE DISEASE: Atypical femoral fractures: risks and benefits of long-term treatment of osteoporosis with anti-resorptive therapy. Adler RA Eur J Endocrinol; 2018 Mar; 178(3):R81-R87. PubMed ID: 29339529 [TBL] [Abstract][Full Text] [Related]
6. Controversies in osteoporosis management: concerns about bisphosphonates and when are "drug holidays" required? McClung M Clin Obstet Gynecol; 2013 Dec; 56(4):743-8. PubMed ID: 24177063 [TBL] [Abstract][Full Text] [Related]
7. [Intermittent long-term administration of intravenous bisphosphonates for treatment of osteoporosis]. Miyakoshi N Clin Calcium; 2014 Jan; 24(1):93-9. PubMed ID: 24369285 [TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates in the treatment of osteoporosis. Diab DL; Watts NB Endocrinol Metab Clin North Am; 2012 Sep; 41(3):487-506. PubMed ID: 22877426 [TBL] [Abstract][Full Text] [Related]
9. [Is SSBT associated with atypical femoral fracture? SSBT isn't associated with atypical femoral fracture]. Soen S Clin Calcium; 2012 Jun; 22(6):919-22. PubMed ID: 22653034 [TBL] [Abstract][Full Text] [Related]
10. Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies. Hanley DA; McClung MR; Davison KS; Dian L; Harris ST; Miller PD; Lewiecki EM; Kendler DL; Am J Med; 2017 Jul; 130(7):862.e1-862.e7. PubMed ID: 28359721 [TBL] [Abstract][Full Text] [Related]
11. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday. Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963 [TBL] [Abstract][Full Text] [Related]
12. Atypical femur fracture during bisphosphonate drug holiday: a case series. Lovy AJ; Koehler SM; Keswani A; Joseph D; Hasija R; Ghillani R Osteoporos Int; 2015 Jun; 26(6):1755-8. PubMed ID: 25832177 [TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates for the prevention and treatment of osteoporosis. Maraka S; Kennel KA BMJ; 2015 Sep; 351():h3783. PubMed ID: 26333528 [TBL] [Abstract][Full Text] [Related]
14. Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Emkey RD; Ettinger M Am J Med; 2006 Apr; 119(4 Suppl 1):S18-24. PubMed ID: 16563937 [TBL] [Abstract][Full Text] [Related]
16. [Osteoporosis treatment can be discontinued based on an individual assessment]. Eiken PA; Abrahamsen B Ugeskr Laeger; 2017 Jan; 179(2):. PubMed ID: 28074765 [TBL] [Abstract][Full Text] [Related]
17. [Combination and sequential therapy using bisphosphonates.]. Okazaki R Clin Calcium; 2017; 27(2):263-271. PubMed ID: 28123129 [TBL] [Abstract][Full Text] [Related]
18. Theoretical consideration of the effect of drug holidays on BMD and tissue age. Hernandez CJ; Lopez HK; Lane JM Osteoporos Int; 2014 May; 25(5):1577-84. PubMed ID: 24570296 [TBL] [Abstract][Full Text] [Related]
19. [Current Topics on Vitamin D. Combined therapy of anti-resorptive drug and active vitamin D]. Endo I Clin Calcium; 2015 Mar; 25(3):433-8. PubMed ID: 25716817 [TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis: pros. Rossini M; Orsolini G; Viapiana O; Adami S; Gatti D Endocrine; 2015 Aug; 49(3):620-7. PubMed ID: 25649760 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]